慢性阻塞性肺病和气喘治疗设备市场规模、份额和成长分析（按产品、适应症、通路和地区划分）—产业预测（2026-2033 年）

全球 COPD 和气喘治疗设备市场规模预计在 2024 年达到 511.7 亿美元，从 2025 年的 536.8 亿美元成长到 2033 年的 787 亿美元，在预测期（2026-2033 年）内复合年增长率为 4.9%。

由于慢性阻塞性肺病（COPD）和气喘的盛行率不断上升以及技术的进步，COPD和气喘治疗设备市场正经历显着增长。 COPD的特征是气流阻塞、呼吸困难和持续咳嗽等症状，而气喘则会损害气道，导致喘息和胸闷，这两种疾病都需要有效的治疗方案。用于雾化吸入药物的肺部给药装置在控制这些疾病中发挥关键作用。随着人口老化和气喘病例的显着增加，对这些装置的需求持续增长。这一趋势显示全球对有效呼吸护理解决方案的迫切需求，从而推动了该行业的创新和市场扩张。

推动全球慢性阻塞性肺病和气喘治疗设备市场发展的因素

慢性阻塞性肺病（COPD）、气喘和肺气肿等呼吸系统疾病的日益流行是全球COPD和气喘治疗设备市场的主要驱动力。这种日益增长的盛行率推动了人们对即时有效治疗方法（包括急救药物）的需求，尤其是在气喘发作期间。此外，政府为提高公众对COPD和气喘症状的认识而采取的措施也促进了市场成长。同时，製造商正日益专注于创新和开发携带式吸入器，随着患者寻求更便利且高效的呼吸管理方案，这进一步推动了该市场的扩张。

限制全球慢性阻塞性肺病和气喘治疗设备市场的因素

全球慢性阻塞性肺病（COPD）和气喘治疗设备市场的成长可能受到多种因素的阻碍。与定量喷雾吸入器（MDI）相关的环境问题以及各种吸入设备和治疗方法的高成本都加剧了市场挑战。激烈的价格竞争也可能进一步影响盈利。此外，报销支持不足和关键药物专利到期等问题也可能限制该领域的扩张机会。另外，用于製造这些设备的材料品质下降也对市场发展构成了额外的障碍。

全球慢性阻塞性肺病和气喘治疗设备市场趋势

受数位吸入器技术进步的推动，全球慢性阻塞性肺病（COPD）和气喘治疗设备市场正经历显着成长。这些创新设备不仅能将药物直接输送到肺部，最大限度地减少全身副作用，还提供先进的监测和依从性支持功能，从而改善患者的治疗效果。随着医疗保健领域越来越重视个人化和预防性治疗方法，对客製化呼吸系统解决方案的需求也日益增长。吸入器使用不当和依从性低等挑战，促使人们开发出易于使用的设备，这些设备整合了病患教育工具和即时回馈功能，最终目标是减少病情加重，并改善慢性呼吸系统疾病的管理。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球慢性阻塞性肺病和气喘治疗设备市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 吸入器
  • 药物粉末吸入器（DPI）
  • 定量喷雾吸入器（MDI）
  • 缓雾吸入器
• 喷雾器
  • 压缩式雾化器
  • 超音波雾化器
  • 网状雾化器

全球慢性阻塞性肺病和气喘治疗设备市场规模（按适应症和复合年增长率划分）（2026-2033 年）

• 气喘
• COPD

全球慢性阻塞性肺病和气喘治疗设备市场规模（按分销管道和复合年增长率划分）（2026-2033 年）

• 零售药房
• 医院
• 网路药房

全球慢性阻塞性肺病及气喘治疗设备市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• AstraZeneca Plc.（United Kingdom）
• GlaxoSmithKline Plc.（United Kingdom）
• Merck & Co., Inc.（United States）
• Novartis AG（Switzerland）
• 3M Company（United States）
• Baxter International Inc.（United States）
• ResMed Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Cipla Ltd.（India）
• Omron Healthcare, Inc.（Japan）
• Invacare Corporation（United States）
• Masimo Corporation（United States）
• Nihon Kohden Corporation（Japan）
• Getinge AB（Sweden）
• Smiths Medical（United Kingdom）
• Allied Healthcare Products, Inc.（United States）
• Aerogen Ltd.（Ireland）
• PARI Medical Holding GmbH（Germany）

结论与建议

Global COPD and Asthma Devices Market size was valued at USD 51.17 Billion in 2024 and is poised to grow from USD 53.68 Billion in 2025 to USD 78.7 Billion by 2033, growing at a CAGR of 4.9% during the forecast period (2026-2033).

The market for chronic obstructive pulmonary disease (COPD) and asthma devices is witnessing substantial growth due to the rising prevalence of these respiratory conditions and advancements in technology. COPD, characterized by airflow obstruction and symptoms such as shortness of breath and persistent cough, alongside asthma, which damages airways and can cause wheezing and chest tightness, necessitates effective treatment solutions. Pulmonary medication delivery devices, designed to aerosolize medications for inhalation, play a crucial role in managing these illnesses. With an increasing elderly population and a significant rise in asthma cases, the demand for these devices continues to soar. This trend underscores the urgent need for effective respiratory care solutions worldwide, driving innovation and market expansion in the industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global COPD and Asthma Devices market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global COPD and Asthma Devices Market Segments Analysis

Global COPD and Asthma Devices Market is segmented by Product, Indication, Distribution Channel and region. Based on Product, the market is segmented into Inhalers and Nebulizers. Based on Indication, the market is segmented into Asthma and COPD. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospitals and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global COPD and Asthma Devices Market

The global market for COPD and asthma devices is being significantly propelled by the increasing incidence of respiratory conditions such as COPD, asthma, and emphysema. This rise in prevalence has led to an amplified demand for immediate and effective treatments, particularly rescue medications during sudden asthma attacks. Moreover, government initiatives aimed at improving awareness of COPD and asthma symptoms are contributing to market growth. Simultaneously, manufacturers are intensifying their efforts to innovate and develop portable inhalation devices, further driving the expansion of this market as patients seek more convenient and efficient solutions for managing their respiratory difficulties.

Restraints in the Global COPD and Asthma Devices Market

The growth of the global COPD and asthma devices market is likely to be hindered by several factors. Environmental concerns associated with metered dose inhalers (MDIs) contribute to market challenges, alongside the high costs associated with a variety of inhalation devices and treatments. The presence of intense price competition can further impact profitability. Additionally, issues such as inadequate reimbursement support and the expiration of patents for significant medications may limit expansion opportunities in this sector. Furthermore, the decline in quality of materials used in the production of these devices presents additional obstacles that could impede market progress.

Market Trends of the Global COPD and Asthma Devices Market

The Global COPD and Asthma Devices market is experiencing significant growth driven by advancements in digital inhaler technology. These innovative devices not only enhance medication delivery directly to the lungs, minimizing systemic side effects but also offer sophisticated monitoring and adherence features that improve patient outcomes. As the healthcare sector increasingly prioritizes personalized and proactive treatment approaches, the demand for tailored respiratory solutions is surging. Challenges such as incorrect inhaler technique and low adherence rates are prompting the development of user-friendly devices that integrate educational tools and real-time feedback for patients, ultimately aiming to reduce exacerbations and enhance the management of chronic respiratory diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global COPD and Asthma Devices Market Size by Product & CAGR (2026-2033)

• Market Overview
• Inhalers
  • Drug Powdered Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Soft Mist Inhalers
• Nebulizers
  • Compressor Nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers

Global COPD and Asthma Devices Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Asthma
• COPD

Global COPD and Asthma Devices Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Retail Pharmacies
• Hospitals
• Online Pharmacies

Global COPD and Asthma Devices Market Size & CAGR (2026-2033)

• North America (Product, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Product, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca Plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3M Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ResMed Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omron Healthcare, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invacare Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Masimo Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nihon Kohden Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smiths Medical (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allied Healthcare Products, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerogen Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PARI Medical Holding GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations